Free Trial

ESSA Pharma (EPIX) Competitors

$4.81
-0.39 (-7.50%)
(As of 01:19 PM ET)

EPIX vs. CVAC, IRWD, BCYC, VRNA, IRON, SAVA, ELVN, GYRE, IMNM, and ABVX

Should you be buying ESSA Pharma stock or one of its competitors? The main competitors of ESSA Pharma include CureVac (CVAC), Ironwood Pharmaceuticals (IRWD), Bicycle Therapeutics (BCYC), Verona Pharma (VRNA), Disc Medicine (IRON), Cassava Sciences (SAVA), Enliven Therapeutics (ELVN), Gyre Therapeutics (GYRE), Immunome (IMNM), and ABIVAX Société Anonyme (ABVX). These companies are all part of the "pharmaceutical preparations" industry.

ESSA Pharma vs.

CureVac (NASDAQ:CVAC) and ESSA Pharma (NASDAQ:EPIX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment, community ranking and analyst recommendations.

CureVac presently has a consensus price target of $6.00, indicating a potential upside of 48.51%. ESSA Pharma has a consensus price target of $16.50, indicating a potential upside of 236.05%. Given CureVac's stronger consensus rating and higher possible upside, analysts clearly believe ESSA Pharma is more favorable than CureVac.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CureVac
1 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.75
ESSA Pharma
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

ESSA Pharma received 327 more outperform votes than CureVac when rated by MarketBeat users. Likewise, 76.37% of users gave ESSA Pharma an outperform vote while only 51.16% of users gave CureVac an outperform vote.

CompanyUnderperformOutperform
CureVacOutperform Votes
22
51.16%
Underperform Votes
21
48.84%
ESSA PharmaOutperform Votes
349
76.37%
Underperform Votes
108
23.63%

In the previous week, CureVac had 2 more articles in the media than ESSA Pharma. MarketBeat recorded 5 mentions for CureVac and 3 mentions for ESSA Pharma. CureVac's average media sentiment score of 1.52 beat ESSA Pharma's score of 0.75 indicating that ESSA Pharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CureVac
3 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
ESSA Pharma
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

ESSA Pharma has a net margin of 0.00% compared to ESSA Pharma's net margin of -463.49%. CureVac's return on equity of -19.46% beat ESSA Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
CureVac-463.49% -49.22% -33.85%
ESSA Pharma N/A -19.46%-18.96%

ESSA Pharma has lower revenue, but higher earnings than CureVac. ESSA Pharma is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CureVac$58.18M15.32-$281.58M-$1.33-2.99
ESSA PharmaN/AN/A-$26.58M-$0.63-7.63

17.3% of CureVac shares are held by institutional investors. Comparatively, 75.1% of ESSA Pharma shares are held by institutional investors. 14.7% of ESSA Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

CureVac has a beta of 2.68, suggesting that its share price is 168% more volatile than the S&P 500. Comparatively, ESSA Pharma has a beta of 1.81, suggesting that its share price is 81% more volatile than the S&P 500.

Summary

ESSA Pharma beats CureVac on 13 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EPIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EPIX vs. The Competition

MetricESSA PharmaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$213.37M$7.30B$5.27B$8.36B
Dividend YieldN/A2.65%2.80%4.06%
P/E Ratio-7.6322.26177.9318.36
Price / SalesN/A266.672,299.7476.05
Price / CashN/A32.7633.9230.83
Price / Book1.465.614.934.28
Net Income-$26.58M$147.13M$109.89M$215.80M
7 Day Performance-17.35%-1.18%-0.69%-0.84%
1 Month Performance-18.89%-0.17%-0.08%-0.75%
1 Year Performance49.84%-5.92%0.55%2.16%

ESSA Pharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CVAC
CureVac
2.8722 of 5 stars
$4.49
-10.0%
$8.33
+85.6%
-57.3%$1.01B$58.18M-3.381,172Short Interest ↑
Gap Down
IRWD
Ironwood Pharmaceuticals
3.9152 of 5 stars
$6.35
-1.6%
$18.40
+189.8%
-44.1%$993.96M$413.55M-0.94267Insider Selling
BCYC
Bicycle Therapeutics
2.2568 of 5 stars
$23.04
-0.3%
$46.86
+103.4%
-5.0%$989.05M$41.61M-5.18284Short Interest ↓
Positive News
VRNA
Verona Pharma
1.9479 of 5 stars
$12.13
+1.0%
$33.50
+176.2%
-32.4%$970.60M$460,000.00-15.7579Positive News
IRON
Disc Medicine
2.9313 of 5 stars
$39.12
+7.3%
$57.71
+47.5%
-20.5%$967.05MN/A-11.5774Positive News
SAVA
Cassava Sciences
3.3656 of 5 stars
$19.63
-1.6%
$131.00
+567.3%
+8.2%$956.65MN/A-9.0529
ELVN
Enliven Therapeutics
1.7021 of 5 stars
$20.94
+3.7%
$34.00
+62.4%
+10.4%$950.15MN/A-10.8546Analyst Forecast
News Coverage
GYRE
Gyre Therapeutics
0.3366 of 5 stars
$11.09
+3.1%
N/AN/A$920.09M$113.45M0.00593Short Interest ↑
Gap Up
IMNM
Immunome
2.0813 of 5 stars
$15.20
+0.3%
$29.80
+96.1%
+221.9%$911.54M$14.02M-2.0155Positive News
ABVX
ABIVAX Société Anonyme
2.0115 of 5 stars
$14.30
+2.5%
$34.20
+139.2%
N/A$899.58MN/A0.0061Short Interest ↑
News Coverage
Positive News
Gap Down

Related Companies and Tools

This page (NASDAQ:EPIX) was last updated on 6/13/2024 by MarketBeat.com Staff

From Our Partners